You are viewing the site in preview mode

Skip to main content


Fig. 8 | Journal for ImmunoTherapy of Cancer

Fig. 8

From: Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

Fig. 8

Long-term curative responses can be mediated in mice without lymphodepletion by depleting host CD4+ T cells and activating APCs with TLR4 agonists LPS. (a) Scheme for treating non-irradiated mice with CD4 depleting antibody, a tripartite ACT treatment and LPS. (b) Tumor eradication via ACT can be achieved without host preconditioning via antibody depleting CD4 lymphocytes that act as Treg and cytokine sinks and activating innate immunity via TLR signaling. One day before ACT, mice were antibody depleted of host CD4+ T cells and subsequently administered every other day for a total of 5 doses. The ACT treatment regimen was comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100 vaccination and hIL-2 or were left untreated. One day after ACT, mice received 2 μg of LPS or were left untreated. Data shown (mean ± SEM, 5 mice per group) are representative of 4 independent experiments. NT (black diamond) vs. PFI, PFI + LPS, or PFI + anti-CD4, *P < .05. PFI + LPS + anti-CD4 (black circle) vs. all groups P < 0.001, ANOVA

Back to article page